In vivo imaging of alpha-synuclein with antibody-based PET.


Journal

Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217

Informations de publication

Date de publication:
01 05 2022
Historique:
received: 04 07 2021
revised: 05 01 2022
accepted: 02 02 2022
pubmed: 13 2 2022
medline: 15 4 2022
entrez: 12 2 2022
Statut: ppublish

Résumé

The protein alpha-synuclein (αSYN) plays a central role in synucleinopathies such as Parkinsons's disease (PD) and multiple system atrophy (MSA). Presently, there are no selective αSYN positron emission tomography (PET) radioligands that do not also show affinity to amyloid-beta (Aβ). We have previously shown that radiolabeled antibodies, engineered to enter the brain via the transferrin receptor (TfR), is a promising approach for PET imaging of intrabrain targets. In this study, we used this strategy to visualize αSYN in the living mouse brain. Five bispecific antibodies, binding to both the murine TfR and αSYN were generated and radiolabeled with iodine-125 or iodine-124. All bispecific antibodies bound to αSYN and mTfR before and after radiolabelling in an ELISA assay, and bound to brain sections prepared from αSYN overexpressing mice as well as human PD- and MSA subjects, but not control tissues in autoradiography. Brain concentrations of the bispecific antibodies were between 26 and 63 times higher than the unmodified IgG format 2 h post-injection, corresponding to about 1.5% of the injected dose per gram brain tissue. Additionally, intrastriatal αSYN fibrils were visualized with PET in an αSYN deposition mouse model with one of the bispecific antibodies, [

Identifiants

pubmed: 35149134
pii: S0028-3908(22)00044-2
doi: 10.1016/j.neuropharm.2022.108985
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Antibodies, Bispecific 0
alpha-Synuclein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108985

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Sahar Roshanbin (S)

Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden. Electronic address: sahar.roshanbin@pubcare.uu.se.

Mengfei Xiong (M)

Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Greta Hultqvist (G)

Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

Linda Söderberg (L)

BioArctic, Stockholm, Sweden.

Olof Zachrisson (O)

BioArctic, Stockholm, Sweden.

Silvio Meier (S)

Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Sara Ekmark-Lewén (S)

Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Joakim Bergström (J)

Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Martin Ingelsson (M)

Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden; Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada; Department of Medicine and Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.

Dag Sehlin (D)

Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Stina Syvänen (S)

Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH